Regenxbio Inc
(NAS:RGNX)
$
9.92
-0.09 (-0.9%)
Market Cap: 491.49 Mil
Enterprise Value: 320.09 Mil
PE Ratio: 0
PB Ratio: 1.63
GF Score: 65/100 Regenxbio Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023 / 07:35PM GMT
Release Date Price:
$19.72
(-9.17%)
Luca Issi
RBC Capital Markets - Analyst
Thanks. Hello, everybody. I'm Luca Issi, a senior biotech analyst here at RBC Capital Markets. And today, it's a great privilege to have REGENXBIO with us for a fireside chat. Representing the company, we have Ram Palanki, Executive Vice President of Commercial Strategy and Operation.
Ram, thanks again for joining us. How are you doing today?
Ram Palanki
REGENXBIO Inc. - EVP, Commercial Strategy & Operations
I'm good, man. How are you?
Questions & Answers
Luca Issi
RBC Capital Markets - Analyst
Good. Good, good, good. We have a long list of questions here. But maybe before we ask you about the individual program, it would be just great if you could give us a little bit of a big-picture overview of what progress has the organization made over the last few months? And then, most importantly, what's ahead here for REGENXBIO?
Ram Palanki
REGENXBIO Inc. - EVP, Commercial Strategy & Operations
Yeah. Thanks
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot